What is acute lymphoblastic leukaemia (ALL?)

Acute lymphoblastic leukaemia (ALL) is an acute leukaemia. Acute means that it develops very quickly. In ALL, white blood cells known as lymphocytes multiply in an uncontrolled manner in the bone marrow.

Lab tests icon: a microscope

About ALL

Acute lymphoblastic leukaemia (ALL) is an acute leukaemia. Acute means that it develops very quickly. In ALL, white blood cells known as lymphocytes multiply in an uncontrolled manner in the bone marrow. Lymphocytes help the body fight infections as part of the immune system. Of the three types of lymphocytes that exist, only the B-cell and T-cell lymphocytes are involved in ALL. Natural killer cell (NK-cell) lymphocytes lead to a different type of leukaemia, not covered here.

In the United Kingdom (UK), the incidence of ALL (both B-cell and T-cell ALL) is 1.1 per 100,000 people per year. This means that around 800 people in the UK are given a diagnosis of ALL every year.

In adults with ALL:

  • 75% of cases involve early immature B-cell lymphocytes (B-cells)
  • 25% of cases involve early immature T-cell lymphocytes (T-cells)

We have more information about B-cell ALL and T-cell ALL, why they develop, and how they are diagnosed and treated.

Help us improve our information

We aim to provide information that’s reliable, up-to-date, and covers what matters to you. Please complete our short survey to help us improve our information and make sure it meets your needs.

About our information

This information is aimed at people in the UK. We do our best to make sure it is accurate and up to date but it should not replace advice from your health professional. Find out more about our information.

Page last reviewed: 30 June 2023

Updated January 2026

Next review due: 30 June 2026

Need help understanding this information?

Our support team is here to answer your questions and provide guidance.

Contact Support

Subscribe today

Subscribe to receive news, updates and ways to support our work from Leukaemia Care. By subscribing, you agree to receive emails from us. You can unsubscribe at any time. Read our privacy policy.